Lack of response to midostaurin in a patient with vulvar melanoma harboring an unusual KIT D816Y mutation that emerged after a previous treatment with imatinib
-
Published:2023
Issue:
Volume:1
Page:100009
-
ISSN:2772-6118
-
Container-title:EJC Skin Cancer
-
language:en
-
Short-container-title:EJC Skin Cancer
Author:
Braud AntoineORCID,
Pencreach Erwan,
Lipsker Dan
Reference6 articles.
1. Vulvar melanoma: molecular characteristics, diagnosis, surgical management, and medical treatment;Wohlmuth;Am. J. Clin. Dermatol.,2021
2. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin;Hodi;J. Clin. Oncol.,2013
3. Differential activity of avapritinib in patients with metastases from mucosal melanoma and thymic carcinoma harbouring KIT exon 17 mutations: Initial experience from a Compassionate Use Program in Italy;Corti;Eur. J. Cancer,2022
4. Cutaneous melanoma versus vulvovaginal melanoma-risk factors, pathogenesis and comparison of immunotherapy efficacy;Lorenz;Cancers (Basel),2022
5. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group;Pascual;Ann. Oncol.,2022